Literature DB >> 19965778

Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia.

Lisa M Nilsson-Berglund1, Anna V Zetterqvist, Jenny Nilsson-Ohman, Mikael Sigvardsson, Laura V González Bosc, Maj-Lis Smith, Albert Salehi, Elisabet Agardh, Gunilla Nordin Fredrikson, Carl-David Agardh, Jan Nilsson, Brian R Wamhoff, Anna Hultgårdh-Nilsson, Maria F Gomez.   

Abstract

OBJECTIVE: Hyperglycemia is a recognized risk factor for cardiovascular disease in diabetes. Recently, we reported that high glucose activates the Ca(2+)/calcineurin-dependent transcription factor nuclear factor of activated T cells (NFAT) in arteries ex vivo. Here, we sought to determine whether hyperglycemia activates NFAT in vivo and whether this leads to vascular complications. METHODS AND
RESULTS: An intraperitoneal glucose-tolerance test in mice increased NFATc3 nuclear accumulation in vascular smooth muscle. Streptozotocin-induced diabetes resulted in increased NFATc3 transcriptional activity in arteries of NFAT-luciferase transgenic mice. Two NFAT-responsive sequences in the osteopontin (OPN) promoter were identified. This proinflammatory cytokine has been shown to exacerbate atherosclerosis and restenosis. Activation of NFAT resulted in increased OPN mRNA and protein in native arteries. Glucose-induced OPN expression was prevented by the ectonucleotidase apyrase, suggesting a mechanism involving the release of extracellular nucleotides. The calcineurin inhibitor cyclosporin A or the novel NFAT blocker A-285222 prevented glucose-induced OPN expression. Furthermore, diabetes resulted in higher OPN expression, which was significantly decreased by in vivo treatment with A-285222 for 4 weeks or prevented in arteries from NFATc3(-/-) mice.
CONCLUSIONS: These results identify a glucose-sensitive transcription pathway in vivo, revealing a novel molecular mechanism that may underlie vascular complications of diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965778      PMCID: PMC2823568          DOI: 10.1161/ATVBAHA.109.199299

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

1.  Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo.

Authors:  Oliver G McDonald; Brian R Wamhoff; Mark H Hoofnagle; Gary K Owens
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  The pathobiology of diabetic complications: a unifying mechanism.

Authors:  Michael Brownlee
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

3.  High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention.

Authors:  Ryuichi Kato; Yukihiko Momiyama; Reiko Ohmori; Nobukiyo Tanaka; Hiroaki Taniguchi; Koh Arakawa; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01       Impact factor: 8.311

4.  High glucose activates nuclear factor of activated T cells in native vascular smooth muscle.

Authors:  Jenny Nilsson; Lisa M Nilsson; Yung-Wu Chen; Jeffery D Molkentin; David Erlinge; Maria F Gomez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-02-09       Impact factor: 8.311

5.  Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model.

Authors:  Zhimin Liu; Chunxiang Zhang; Nagadhara Dronadula; Quanyi Li; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2005-01-28       Impact factor: 5.157

Review 6.  Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels.

Authors:  Jaime A Davidson
Journal:  Curr Med Res Opin       Date:  2004-12       Impact factor: 2.580

7.  UTP induces osteopontin expression through a coordinate action of NFkappaB, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells.

Authors:  Marie-Ange Renault; Sandra Jalvy; Mylène Potier; Isabelle Belloc; Elisabeth Genot; Lodewijk V Dekker; Claude Desgranges; Alain-Pierre Gadeau
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

8.  Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients.

Authors:  Hiroshi Yamaguchi; Masahiko Igarashi; Akihiko Hirata; Hiromi Tsuchiya; Kazuhiko Sugiyama; Yoshihiro Morita; Yumi Jimbu; Hiroshi Ohnuma; Makoto Daimon; Makoto Tominaga; Takeo Kato
Journal:  Endocr J       Date:  2004-10       Impact factor: 2.349

9.  Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.

Authors:  C M Giachelli; N Bae; M Almeida; D T Denhardt; C E Alpers; S M Schwartz
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 10.  Hyperglycemia and microvascular and macrovascular disease in diabetes.

Authors:  R Klein
Journal:  Diabetes Care       Date:  1995-02       Impact factor: 19.112

View more
  35 in total

Review 1.  The touching story of purinergic signaling in epithelial and endothelial cells.

Authors:  Jenny Öhman; David Erlinge
Journal:  Purinergic Signal       Date:  2012-04-24       Impact factor: 3.765

2.  Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin Polymerization.

Authors:  Tran Thi Hien; Karolina M Turczyńska; Diana Dahan; Mari Ekman; Mario Grossi; Johan Sjögren; Johan Nilsson; Thomas Braun; Thomas Boettger; Eliana Garcia-Vaz; Karin Stenkula; Karl Swärd; Maria F Gomez; Sebastian Albinsson
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

3.  Calreticulin Regulates Neointima Formation and Collagen Deposition following Carotid Artery Ligation.

Authors:  Kurt A Zimmerman; Dongqi Xing; Manuel A Pallero; Ailing Lu; Masahito Ikawa; Leland Black; Kenneth L Hoyt; Janusz H Kabarowski; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2016-02-25       Impact factor: 1.934

Review 4.  The role of nuclear factor of activated T cells in pulmonary arterial hypertension.

Authors:  Rui Chen; Jinchuan Yan; Peijing Liu; Zhongqun Wang; Cuiping Wang; Wei Zhong; Liangjie Xu
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

5.  Na(+)/H (+) exchanger isoform 1 induced osteopontin expression in cardiomyocytes involves NFAT3/Gata4.

Authors:  Mohamed Mlih; Nabeel Abdulrahman; Alain-Pierre Gadeau; Iman A Mohamed; Maiy Jaballah; Fatima Mraiche
Journal:  Mol Cell Biochem       Date:  2015-03-11       Impact factor: 3.396

6.  Nuclear factor of activated T cells regulates neutrophil recruitment, systemic inflammation, and T-cell dysfunction in abdominal sepsis.

Authors:  Su Zhang; Lingtao Luo; Yongzhi Wang; Maria F Gomez; Henrik Thorlacius
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

7.  Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells.

Authors:  C Goettsch; M Rauner; C Hamann; K Sinningen; U Hempel; S R Bornstein; L C Hofbauer
Journal:  Diabetologia       Date:  2011-06-24       Impact factor: 10.122

8.  AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus.

Authors:  Matthew A Nystoriak; Madeline Nieves-Cintrón; Patrick J Nygren; Simon A Hinke; C Blake Nichols; Chao-Yin Chen; Jose L Puglisi; Leighton T Izu; Donald M Bers; Mark L Dell'acqua; John D Scott; Luis F Santana; Manuel F Navedo
Journal:  Circ Res       Date:  2013-12-09       Impact factor: 17.367

9.  Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors.

Authors:  Daniel J Lightell; T Cooper Woods
Journal:  Ochsner J       Date:  2013

10.  NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.

Authors:  Juan Manuel Ramiro-Diaz; Carlos H Nitta; Levi D Maston; Simon Codianni; Wieslawa Giermakowska; Thomas C Resta; Laura V Gonzalez Bosc
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-08       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.